Podcast: Verzenio Improves Overall Survival in HR+ HER2- Adv BC

moderators

Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer
Sep 28, 2022

Dr. Matthew Goetz explains the latest results from the MONARCH 3 study on Verzenio.

At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.

Listen to the podcast to hear Dr. Goetz explain:

• how Verzenio works
• the purpose of the MONARCH 3 study
• the difference between progression-free and overall survival and why each is important
• Verzenio side effects
• what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer

Listen now or read the transcript.